Zum Hauptinhalt springen
xMedica

NCT07784270ClinicalTrials.gov

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.
Diese Studie kontaktieren

Kurz gefasst

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

Phase 31.500 Teilnehmende gesucht230 Studienzentren16 Länder

Kategorien

In 1 Register registriert

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 5 days after the recorded start)First posted 2026-08-25; recorded start 2026-08-20
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 2 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 218 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 1,500 participants (target), run at 230 sites, across 16 countries.

How this score is built
  • Enrolment32/40

    1,500 participants (target)

  • Site count25/25

    218 sites

  • Country count15/15

    16 countries

  • Planned duration7/10

    Planned over about 24 months

  • Sponsor scale10/10

    AstraZeneca has led 1,017 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

This is a Phase III, global, randomized, parallel-group, double-blind, multicentre study to assess the efficacy and safety of AZD6234 compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM) and obesity or overweight. Eligible participants will be randomized to either receive AZD6234 or matching placebo respectively.

Erkrankungen

  • Obesity or Overweight
  • Diabetes Mellitus, Type 2

Eignung

Eignung
GeschlechtAlle
Alter18 Years – Kein Höchstalter
Gesunde FreiwilligeNein

Eignung im Wortlaut des Registers

Inclusion Criteria: * Males \& females (inclusive of all gender identities) age ≥18 years * BMI ≥27 kg/m2 * Diagnosed with T2DM ≥90 days prior to Screening * HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling) * Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation * History of at least one self-reported unsuccessful attempt to lose body weight in lifetime Exclusion Criteria: * Obesity primarily caused by other endocrine disorders * Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening * Significant hepatobiliary disease and/or any of the following results at Screening: * ALT ≥ 3.0 X ULN * AST ≥ 3.0 X ULN * TBL \> 1.5 X ULN (except for cases of known Gilbert's Syndrome) * Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation * Use of insulin therapy for T2DM within 3 months prior to screening

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
StudientypInterventionell
PhasePhase 3
ZuteilungRandomisiert
InterventionsmodellPARALLEL
Primäres ZielTREATMENT
VerblindungQUADRUPLE (4)
Teilnahme1.500 Teilnehmende gesucht

Sponsor und Mitwirkende

  • AstraZeneca Sponsor

Studienarme und Interventionen

  • AZD6234 Dose 1EXPERIMENTAL

    AZD6234 Dose 1

  • AZD6234 Dose 2EXPERIMENTAL

    AZD6234 Dose 2

  • PlaceboPLACEBO_COMPARATOR

    Matching placebo

Interventionen

  • Arzneimittel Lenbelintide

    IMP injected subcutaneously, once a week. Unit dose strength as per CSP.

  • Arzneimittel Placebo

    Placebo matching IMP dose injected subcutaneously, once a week.

Endpunkte

  1. Primärer Endpunkt

    Percent change in body weight from baseline at 68 weeks of treatment.

    To evaluate the effect of AZD6234 compared to placebo in percent body weight change

    Zeitrahmen 68 weeks

  2. Sekundärer Endpunkt

    Absolute change in weight (kg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo on absolute change in weight

    Zeitrahmen 68 weeks

  3. Sekundärer Endpunkt

    Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo in body weight loss of at least 5%

    Zeitrahmen 68 weeks

  4. Sekundärer Endpunkt

    Achievement of at least 10 % body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo in body weight loss of at least 10%

    Zeitrahmen 68 weeks

  5. Sekundärer Endpunkt

    Change in haemoglobin A1C from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 on haemoglobin A1C change

    Zeitrahmen 68 weeks

  6. Sekundärer Endpunkt

    Change in waist circumference (cm) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo on waist circumference change

    Zeitrahmen 68 weeks

  7. Sekundärer Endpunkt

    Percent change in triglycerides from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo on triglycerides percent change

    Zeitrahmen 68 weeks

  8. Sekundärer Endpunkt

    Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo on systolic blood pressure change

    Zeitrahmen 68 weeks

  9. Sekundärer Endpunkt

    Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset

    Body Composition Sub-study: To evaluate the effect of AZD6234 compared to placebo on body composition change in the DXA subset of participants

    Zeitrahmen 68 weeks

Daten

Daten
Startdatum20. August 2026 (tatsächlich)
Primärer Abschluss9. August 2028 (geschätzt)
Abschluss9. August 2028 (geschätzt)
Erstveröffentlichung25. August 2026 (tatsächlich)
Zuletzt aktualisiert28. Oktober 2026
Ergebnisse veröffentlichtIm Registereintrag nicht angegeben
Status zuletzt bestätigtOktober 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

58 Studienzentren rekrutieren

Argentina

Argentina
EinrichtungStadtBundesland oder RegionStatus
Research SiteBuenos AiresRekrutiert
Research SiteCABARekrutiert
Research SiteCiudad de Buenos AiresRekrutiert
Research SiteMendozaRekrutiert
Research SiteRamos MejíaRekrutierung noch nicht begonnen
Research SiteRosarioRekrutiert
Research SiteSan NicolásRekrutierung noch nicht begonnen

Australia

Australia
EinrichtungStadtBundesland oder RegionStatus
Research SiteBotanyRekrutiert
Research SiteCamberwellRekrutiert
Research SiteCharlestownRekrutiert
Research SiteHelensvaleRekrutiert
Research SiteMaroubraRekrutiert
Research SiteWaitaraRekrutiert

Canada

Canada
EinrichtungStadtBundesland oder RegionStatus
Research SiteCalgaryAlbertaRekrutiert
Research SiteHamiltonOntarioRekrutiert
Research SiteJolietteQuebecRekrutiert
Research SiteMarkhamOntarioRekrutiert
Research SiteMonctonNew BrunswickRekrutiert
Research SiteMontrealQuebecRekrutiert
Research SiteMontrealQuebecRekrutiert
Research SiteNorth YorkOntarioRekrutiert
Research SiteQuébecQuebecRekrutiert
Research SiteSarniaOntarioRekrutiert
Research SiteScarborough VillageOntarioRekrutiert
Research SiteStoney CreekOntarioZurückgezogen
Research SiteStouffvilleOntarioRekrutiert
Research SiteTorontoOntarioRekrutiert
Research SiteTorontoOntarioRekrutiert
Research SiteTrois-RivièresQuebecRekrutiert
Research SiteTruroNova ScotiaRekrutiert
Research SiteVancouverBritish ColumbiaRekrutiert

Chile

Chile
EinrichtungStadtBundesland oder RegionStatus
Research SiteConcepciónRekrutierung noch nicht begonnen
Research SiteConcepciónRekrutierung noch nicht begonnen
Research SiteConcepciónRekrutierung noch nicht begonnen
Research SiteIquiqueRekrutierung noch nicht begonnen
Research SiteLas CondesRekrutierung noch nicht begonnen
Research SiteProvidenciaRekrutierung noch nicht begonnen
Research SiteSantiagoRekrutierung noch nicht begonnen
Research SiteSantiagoRekrutierung noch nicht begonnen
Research SiteSantiagoRekrutierung noch nicht begonnen

China

China
EinrichtungStadtBundesland oder RegionStatus
Research SiteBeijingRekrutierung noch nicht begonnen
Research SiteCangzhouRekrutierung noch nicht begonnen
Research SiteChangchunRekrutierung noch nicht begonnen
Research SiteChengduRekrutierung noch nicht begonnen
Research SiteChengduRekrutierung noch nicht begonnen
Research SiteDanyangRekrutierung noch nicht begonnen
Research SiteGanzhouRekrutierung noch nicht begonnen
Research SiteGuangzhouRekrutierung noch nicht begonnen
Research SiteHuizhouRekrutierung noch nicht begonnen
Research SiteHuzhouRekrutierung noch nicht begonnen

180 weitere Studienzentren sind im Registereintrag aufgeführt.

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

  1. 28. Oktober 2026

    Abschlussdatum nach hinten verschoben

    Primary completion delayed 1 days

    2028-08-082028-08-09

  2. 28. Oktober 2026

    Studienzentrum hinzugefügt

    3 sites added (230 total)

    227230

  3. 22. September 2026

    Status geändert

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  4. 22. September 2026

    Rekrutierung eröffnet

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  5. 22. September 2026

    Abschlussdatum nach vorne verschoben

    Primary completion advanced 1 days

    2028-08-092028-08-08

  6. 22. September 2026

    Studienzentrum hinzugefügt

    9 sites added (227 total)

    218227